We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
LGC Clinical Diagnostics

Download Mobile App




Multiplex Assay Detects Atypical Bacterial Respiratory Pathogens

By LabMedica International staff writers
Posted on 12 May 2011
A single tube assay has been developed that can rapidly detect three atypical bacterial pathogens in clinical specimens from patients with suspected pneumonia. More...


The multiplex polymerase chain reaction (PCR) assay was compared with singleplex assays to determine the presence of Mycoplasma pneumoniae, Chlamydia pneumoniae, and Legionella species and the human ribonuclease P (RNase P) gene.

Scientists at the US Centers for Disease Control and Prevention (CDC; Atlanta, GA, USA), used four distinct hydrolysis probes to detect three of the leading causes of community-acquired pneumonia. The assay was evaluated for specificity and sensitivity by testing against 35 related organisms, a dilution series of each specific target and 197 clinical specimens. In total, 177 nasopharyngeal and/or oropharyngeal swabs were tested by all four singleplex assays in addition to the multiplex assay. Twenty clinical specimens including lung tissue, bronchial lavage, sputa, and spleen tissue were also tested, in triplicate, with the singleplex assay designed specifically to detect Legionella species (Pan-Leg), as well as the multiplex assay.

A comparison to previously validated singleplex real-time PCR assays for each agent was also performed and specificity testing demonstrated no cross-reactivity. The analytical sensitivity for specific pathogen targets in both the singleplex and multiplex was identical at 50 fg, while efficiencies ranged from 82% to 97% for the singleplex assays and from 90% to 100% for the multiplex assay. This multiplex assay provides an overall improvement in the diagnostic capability for these agents by demonstrating a sensitive, high-throughput and rapid method. This procedure may allow for a practical and efficient means to test respiratory clinical specimens for atypical pneumonia agents in health care settings and facilitate an appropriate public health response to outbreaks.

The authors concluded that the use of this assay in surveillance studies may provide greater insight into the etiology and prevalence of atypical bacterial pneumonias among a population. The assay will also facilitate the rapid identification of the causative agent for community acquired pneumonia outbreaks. Widespread availability of this and similar assays may lead to a more effective public health response and expedite appropriate treatment of patients. The study was published in May 2011 in the journal Diagnostic Microbiology and Infectious Disease.

Related Links:
US Centers for Disease Control and Prevention


Platinum Member
ADAMTS-13 Protease Activity Test
ATS-13 Activity Assay
Verification Panels for Assay Development & QC
Seroconversion Panels
POCT Fluorescent Immunoassay Analyzer
FIA Go
Gold Member
Blood Ammonia Test Analyzer
DRI-CHEM NX10N
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image: QIP-MS could predict and detect myeloma relapse earlier compared to currently used techniques (Photo courtesy of Adobe Stock)

Mass Spectrometry-Based Monitoring Technique to Predict and Identify Early Myeloma Relapse

Myeloma, a type of cancer that affects the bone marrow, is currently incurable, though many patients can live for over 10 years after diagnosis. However, around 1 in 5 individuals with myeloma have a high-risk... Read more

Immunology

view channel
Image: The cancer stem cell test can accurately choose more effective treatments (Photo courtesy of University of Cincinnati)

Stem Cell Test Predicts Treatment Outcome for Patients with Platinum-Resistant Ovarian Cancer

Epithelial ovarian cancer frequently responds to chemotherapy initially, but eventually, the tumor develops resistance to the therapy, leading to regrowth. This resistance is partially due to the activation... Read more

Technology

view channel
Image: Ziyang Wang and Shengxi Huang have developed a tool that enables precise insights into viral proteins and brain disease markers (Photo courtesy of Jeff Fitlow/Rice University)

Light Signature Algorithm to Enable Faster and More Precise Medical Diagnoses

Every material or molecule interacts with light in a unique way, creating a distinct pattern, much like a fingerprint. Optical spectroscopy, which involves shining a laser on a material and observing how... Read more

Industry

view channel
Image: The collaboration aims to leverage Oxford Nanopore\'s sequencing platform and Cepheid\'s GeneXpert system to advance the field of sequencing for infectious diseases (Photo courtesy of Cepheid)

Cepheid and Oxford Nanopore Technologies Partner on Advancing Automated Sequencing-Based Solutions

Cepheid (Sunnyvale, CA, USA), a leading molecular diagnostics company, and Oxford Nanopore Technologies (Oxford, UK), the company behind a new generation of sequencing-based molecular analysis technologies,... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.